Document is current
Any future updates will be listed below
-
Authors
Berman, Gabriele https://orcid.org/0009-0008-3390-9508
Lowe, Michael https://orcid.org/0000-0001-5712-3800
Tsermoulas, Georgios https://orcid.org/0000-0001-5658-2335
Sinclair, Alex J. https://orcid.org/0000-0003-2777-5132
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
- License Information
-
More Information
Article History
Received: 14 June 2025
Revised: 16 June 2025
Accepted: 1 July 2025
First Online: 15 July 2025
Competing interests
: SM reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular therapeutix); speaker fees (Teva); Travel (AbbVie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). SM is a section editor at Eye Journal. AS reports consultancy fees from Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva UK and Novartis. She was previously a Director and Chief Scientific Officer with shares at Invex Therapeutics. Authors declare no other financial relationships with any organisations that might have an interest in the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.
